Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$555M |
| 2 |
Citigroup
C
|
+$407M |
| 3 |
Medtronic
MDT
|
+$401M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$392M |
| 5 |
Gilead Sciences
GILD
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.43B |
| 2 |
Amazon
AMZN
|
+$1.32B |
| 3 |
Apple
AAPL
|
+$1.1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$995M |
| 5 |
Bank of America
BAC
|
+$726M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.47% |
| 2 | Technology | 3.02% |
| 3 | Healthcare | 2.92% |
| 4 | Consumer Discretionary | 2.17% |
| 5 | Financials | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
13851
CALL
Vinci Compass Investments Ltd
VINP
$681M
| $993 | ﹤0.01% |
100
-900
| -90% | -$9.59K |
2023 Q1
6 quarters
|
|
13852
CALL
Expensify
EXFY
$212M
| $980 | ﹤0.01% |
+500
| New | +$1.04K |
2024 Q3
0 quarters
|
|
13853
PUT
Ribbon Communications
RBBN
$297M
| $975 | ﹤0.01% |
300
-100
| -25% | -$324 |
2023 Q4
3 quarters
|
|
13854
Presidio Property Trust Inc Series A Warrants
SQFTW
$193K
| $975 | ﹤0.01% |
+27,857
| New | +$891 |
2024 Q3
0 quarters
|
|
13855
PUT
Smith Micro Software
SMSI
$15M
| $961 | ﹤0.01% |
188
-900
| -83% | -$6.35K |
2019 Q3
20 quarters
|
|
13856
CALL
Armata Pharmaceuticals
ARMP
$131M
| $948 | ﹤0.01% |
400
+300
| +300% | +$767 |
2024 Q1
2 quarters
|
|
|
KACLW
13857
DELISTED
Kairous Acquisition Corp. Limited Warrants
KACLW
| $946 | ﹤0.01% |
189,108
+13,279
| +8% | +$100 |
2024 Q2
1 quarter
|
|
|
CLDI.WS
13858
DELISTED
Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
| $926 | ﹤0.01% |
70,701
+200
| +0.3% | +$6 |
2024 Q1
2 quarters
|
|
13859
Neumora Therapeutics
NMRA
$90.8M
| $925 | ﹤0.01% |
70
-860,373
| -100% | -$10M |
2023 Q3
4 quarters
|
|
|
XOSWW
13860
DELISTED
Xos Inc Warrants
XOSWW
| $923 | ﹤0.01% |
31,833
+15,417
| +94% | +$476 |
2024 Q1
2 quarters
|
|
|
OUSTW
13861
DELISTED
Ouster Inc Warrants
OUSTW
| $918 | ﹤0.01% |
35,750
-87
| -0.2% | -$3 |
2024 Q1
2 quarters
|
|
|
PAVMZ
13862
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
| $918 | ﹤0.01% |
42,692
+484
| +1% | +$15 |
2024 Q2
1 quarter
|
|
|
SUP
13863
CALL
DELISTED
Superior Industries International
SUP
| $912 | ﹤0.01% |
300
-300
| -50% | -$959 |
2024 Q2
1 quarter
|
|
13864
PUT
Lineage Cell Therapeutics
LCTX
$233M
| $905 | ﹤0.01% |
1,000
+600
| +150% | +$556 |
2024 Q2
1 quarter
|
|
13865
PUT
Ultralife
ULBI
$109M
| $904 | ﹤0.01% |
100
-2,800
| -97% | -$28.9K |
2022 Q4
7 quarters
|
|
13866
Orion Energy Systems
OESX
$124M
| $888 | ﹤0.01% |
104
-3,710
| -97% | -$35.2K |
2023 Q3
4 quarters
|
|
|
BCAB
13867
CALL
DELISTED
BIOATLA INC
BCAB
| $880 | ﹤0.01% |
10
-44
| -81% | -$3.69K |
2021 Q4
11 quarters
|
|
|
BFAC.WS
13868
DELISTED
Battery Future Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
BFAC.WS
| $879 | ﹤0.01% |
43,930
+21,860
| +99% | +$446 |
2024 Q2
1 quarter
|
|
13869
CALL
IRIDEX
IRIX
$12.6M
| $875 | ﹤0.01% |
500
| – | – |
2023 Q3
4 quarters
|
|
|
TRVG
13870
PUT
trivago
TRVG
$330M
| $865 | ﹤0.01% |
500
+200
| +67% | +$398 |
2024 Q1
2 quarters
|
|
13871
PUT
Aterian
ATER
$11.2M
| $864 | ﹤0.01% |
300
+200
| +200% | +$598 |
2024 Q2
1 quarter
|
|
|
SHCR
13872
PUT
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $852 | ﹤0.01% |
600
-9,800
| -94% | -$13.6K |
2021 Q3
12 quarters
|
|
|
PITAW
13873
DELISTED
Heramba Electric plc Warrants
PITAW
| $842 | ﹤0.01% |
+10,419
| New | +$1.06K |
2024 Q3
0 quarters
|
|
13874
PUT
DiaMedica Therapeutics
DMAC
$450M
| $838 | ﹤0.01% |
200
-800
| -80% | -$2.95K |
2022 Q4
7 quarters
|
|
|
VSEEW
13875
DELISTED
VSEE HEALTH INC WTS 29
VSEEW
| $829 | ﹤0.01% |
20,230
-1,598
| -7% | -$173 |
2024 Q2
1 quarter
|
|
Similar funds
Citadel Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Citadel Advisors held 15,731 positions worth $518B, up 4.9% from $494B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Citadel Advisors's Q3 2024 filing shows 1,612 new, 6,434 increased, 5,866 reduced and 1,610 closed positions. Its largest new stake was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M. The largest sale was Invesco QQQ Trust, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 82% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q3 2024 buy was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M.
- Citadel Advisors added most to NVIDIA in Q3 2024, an estimated $555M increase.
- Citadel Advisors's biggest Q3 2024 reduction was Invesco QQQ Trust, cutting an estimated $1.43B.
- Citadel Advisors fully exited Domino's in Q3 2024, selling an estimated $186M.
- Citadel Advisors's ten largest holdings make up 30% of its $518B portfolio in Q3 2024.
- Citadel Advisors opened 1,612 new positions and closed 1,610 in Q3 2024.
- Citadel Advisors's portfolio value rose 4.9% quarter-over-quarter to $518B.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.